<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858297</url>
  </required_header>
  <id_info>
    <org_study_id>FDASU-RECD 1214403</org_study_id>
    <nct_id>NCT02858297</nct_id>
  </id_info>
  <brief_title>Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus</brief_title>
  <official_title>Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus: A Pilot, Randomized, Clinical and Immunohistochemical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of
      chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect and
      was administrated orally in osteoarthritis and atopic dermatitis therapy. Given the Oral
      lichen planus (OLP) T-cell-mediated pathogenesis; this drug seems to be a promising
      therapeutic option. The investigators compared clinical effectiveness of Glucosamine combined
      with two topical corticosteroid regimens to that of topical corticosteroid alone in
      symptomatic OLP and investigated therapeutic mechanism by examining treatment effect on
      expression of inhibitor kappa kinase alpha (IKKα) and interleukin-8 (IL-8) in OLP lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty patients with Erosive or Atrophic OLP were randomly assigned into Three equal groups
      to receive combination of topical steroid (triamcinolone acetonide 0.1 %) four times per day
      and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks (Group I),
      combination of topical steroid twice daily and glucosamine sulfate 500 mg orally three times
      per day for 8 weeks (Group II), or topical steroid alone four times per day for 8 weeks
      (Group III) all patients were followed up for another treatment free 4 weeks observational
      period. Photographs of the most severe lesion were taken (Marker lesion) in each patient and
      analyzed for Total Ulcerative Area (TUA), Total Atrophic Area (TAA), and Total Reticular Area
      (TRA), patients were also assessed using clinical scores (CS) and visual analogue scale
      (VAS). Pre-treatment and post-treatment specimens were immunohistochemically stained to
      detect expression of IKKα and IL-8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical score</measure>
    <time_frame>change from Baseline at 12 weeks</time_frame>
    <description>&quot;0&quot; represented no lesion/normal mucosa; &quot;1&quot; mild white striae/no erythematous area, &quot;2&quot;white striae with atrophic area less than 1 cm², &quot;3&quot; white striae with atrophic area more than 1 cm², &quot;4&quot; white striae with erosive area less than 1 cm², and &quot;5&quot; white striae with erosive area more than 1 cm²</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IKK-alpha</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
    <description>Inhibitor kappa kinase alpha immunopositive cells count in immunostained section</description>
  </secondary_outcome>
  <other_outcome>
    <measure>VAS</measure>
    <time_frame>change from Baseline at 12 weeks</time_frame>
    <description>Patients ranked the severity of pain on 100-mm visual analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>TUA</measure>
    <time_frame>change from Baseline at 12 weeks</time_frame>
    <description>Surface area of ulcer in marker lesion in mm2</description>
  </other_outcome>
  <other_outcome>
    <measure>TAA</measure>
    <time_frame>change from Baseline at 12 weeks</time_frame>
    <description>Surface area of atrophied red area in marker lesion in mm2</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-8</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
    <description>Mean area fraction of immunopositive IL-8 in section</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Glucosamine/Corticosteroid 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical steroid (triamcinolone acetonide 0.1 %) four times per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucosamine/Corticosteroid 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical steroid (triamcinolone acetonide 0.1 %) twice per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine sulfate</intervention_name>
    <description>Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect</description>
    <arm_group_label>Glucosamine/Corticosteroid 4</arm_group_label>
    <arm_group_label>Glucosamine/Corticosteroid 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
    <description>Topical corticosteroid</description>
    <arm_group_label>Glucosamine/Corticosteroid 4</arm_group_label>
    <arm_group_label>Glucosamine/Corticosteroid 2</arm_group_label>
    <arm_group_label>Corticosteroid</arm_group_label>
    <other_name>Kenalog in orabase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically and Histologically proven painful Bullous/erosive or atrophic forms of OLP

        Exclusion Criteria:

          -  lichenoid lesions

          -  Presence of systemic conditions

          -  Smoking

          -  Known hypersensitivity or severe adverse effects to the treatment drugs or to any
             ingredient of their preparation

          -  Pregnancy or breast-feeding

          -  History of previous treatments potentially effective on OLP in last 3 months

          -  Loss of pliability or flexibility in the tissues involved by the oral lesions of
             lichen planus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala A. Abo el ela, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of dentistry- Ain shams University</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ola Mohamed Ezzatt</investigator_full_name>
    <investigator_title>Lecturer of oral medicine and periodontology</investigator_title>
  </responsible_party>
  <keyword>Oral lichen planus</keyword>
  <keyword>Glucosamine</keyword>
  <keyword>IL-8</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus</mesh_term>
    <mesh_term>Lichen Planus, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

